Last reviewed · How we verify
Azilsartan Trimethylethanolamine
Azilsartan Trimethylethanolamine is a Angiotensin II Receptor Blocker (ARB) Small molecule drug developed by Jiangsu Hansoh Pharmaceutical Co., Ltd.. It is currently in Phase 1 development.
Blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone release to lower blood pressure.
Azilsartan Trimethylethanolamine is a small molecule that acts as a Type-1 angiotensin II receptor antagonist. It is used in a Phase I study to evaluate its single-dose pharmacokinetics in healthy volunteers.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Azilsartan Trimethylethanolamine |
|---|---|
| Sponsor | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| Drug class | Angiotensin II Receptor Blocker (ARB) |
| Modality | Small molecule |
| Phase | Phase 1 |
Mechanism of action
Azilsartan selectively blocks the AT1 receptor, preventing angiotensin II from binding and causing vasoconstriction. This blockade reduces peripheral vascular resistance and decreases aldosterone secretion, leading to reduced blood pressure and improved cardiovascular outcomes.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azilsartan Trimethylethanolamine CI brief — competitive landscape report
- Azilsartan Trimethylethanolamine updates RSS · CI watch RSS
- Jiangsu Hansoh Pharmaceutical Co., Ltd. portfolio CI
Frequently asked questions about Azilsartan Trimethylethanolamine
What is Azilsartan Trimethylethanolamine?
How does Azilsartan Trimethylethanolamine work?
Who makes Azilsartan Trimethylethanolamine?
What drug class is Azilsartan Trimethylethanolamine in?
What development phase is Azilsartan Trimethylethanolamine in?
Related
- Drug class: All Angiotensin II Receptor Blocker (ARB) drugs
- Manufacturer: Jiangsu Hansoh Pharmaceutical Co., Ltd. — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing